US/UK/Canada

Share

Pick a time period -
Tags ( Active)

DexTech Medical's myeloma study fully recruited, preliminary results very positive

The study was conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment has lasted for a total of 14 weeks with 2 doses per month. Three dose levels of OsteoDex (ODX) have been studied, 3mg/kg body weight, 6mg/kg, and 9mg/kg. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital Huddinge. Dr Dorota Knut is the principal investigator at the Department of Hematology at Uddevalla Hospital. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University Hospital

DexTech Medical AB, Interim Report 1 July 2025 – 31 March 2026

The "Company" refers to DexTech Medical AB (org.nr 556664-6203). Summary of the third quarter (2026-01-01 – 2026-03-31) · Net sales amounted to SEK 0.0 million (0.0) · Operating profit amounted to SEK -1.7 million (-1.3) · Earnings per share* SEK -0.09 (-0.07) Summary of the nine-month period (2025-07-01 – 2026-03-31) · Net sales amounted to SEK 0.0 million (0.0) · Operating profit amounted to SEK -4.8 million (-3.7) · Earnings per share* SEK -0.25 (-0.18) · Cash and cash equivalents at the end of the period amounted to SEK 10.1 M (14.7) · More than 80

DexTech Medical's myeloma study, completed at the end of February 2026, concludes with continued strong results

The study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels of OsteoDex (ODX) are studied, 3mg/kg body weight, 6mg/kg, and 9mg/kg. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital Huddinge. Dr Dorota Knut is the principal investigator at the Department of Hematology at Uddevalla Hospital. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University Hospital Solna,

DexTech Medical's Myeloma Study (ODX-MM-001), Dose Group 2 and Dose Group 3

The study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels of ODX are studied, 3mg/kg body weight, 6mg/kg, and 9mg/kg. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital Huddinge. Dr Dorota Knut is the principal investigator at the Department of Hematology at Uddevalla Hospital. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University Hospital Solna, NKS.  Adult

DexTech Medical AB, Bulletin from the Annual General Meeting

Today, November 4, 2025, the Annual General Meeting of DexTech Medical AB was held. All resolutions were passed with the required majority. Resolution on adoption of the income statement and balance sheetThe AGM resolved to adopt the presented income statement and balance sheet. Resolution regarding appropriation of the company's result in accordance with the adopted balance sheetThe AGM resolved to allocate the company's result in accordance with the Board of Directors' proposal, and that no dividend be paid for the financial year 2024/2025. Resolution on discharge from

DexTech Medical AB, Interim report July 1- September 30, 2025

Summary of the first quarter (2025-07-01 – 2025-09-30) · Net sales amounted to MSEK 0.0 (0.0) · Operating profit/loss amounted to MSEK -1.3 (-1.3) · Earnings per share* SEK -0.07 (-0.06) · Cash and cash equivalents at the end of the interim period amounted to MSEK 14.1 (14.7). * Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year. Comments from the CEO  The ongoing

DexTech Medical's Myeloma Study, Dose Group 2, DMC Gives OK for Dose Group 3

The study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels of ODX are studied, 3mg/kg body weight, 6mg/kg, and 9mg/kg. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital Huddinge. Dr Dorota Knut is the principal investigator at the Department of Hematology at Uddevalla Hospital. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University Hospital Solna, NKS.  Adult

DexTech Medical AB, Invitation to open Annual General Meeting and notice

On Tuesday, November 4, 2025, DexTech Medical AB ("DexTech") will hold its Annual General Meeting. Subject to availability, non-shareholders are also welcome to participate without voting rights. At the meeting, the founders, CEO Anders R Holmberg and Medically Responsible Professor Sten Nilsson, among others, will present the company and the clinical situation regarding prostate cancer and multiple myeloma. There will be an opportunity to ask questions to DexTech's Board of Directors and management. Formal notice of the Annual General Meeting is available further down in this press release.

Supplement, DexTech Medical AB: Annual Report 2024-07-01 - 2025-06-30

In the previous press release, the annual report was missing as a PDF.The Board of Directors and the CEO of Dextech Medical AB (DexTech), org.nr. 556664-6203, with its registered office in Stockholm, hereby submits the Annual Report for the financial year 2024-07-01 - 2025-06-30. For more information about DexTech, please contact: Gösta Lundgren - CFO DexTech Medical AB Phone: +46 (0) 707104788 E-mail: gosta.lundgren@dextechmedical.com  DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are

DexTech Medical AB, Annual Report 2024-07-01 - 2025-06-30

The Board of Directors and the CEO of Dextech Medical AB (DexTech), org.nr. 556664-6203, with its registered office in Stockholm, hereby submits the Annual Report for the financial year 2024-07-01 - 2025-06-30. For more information about DexTech, please contact: Gösta Lundgren - CFO DexTech Medical AB Phone: +46 (0) 707104788 E-mail: gosta.lundgren@dextechmedical.com  DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The lead candidate is OsteoDex for the treatment of

DexTech Medical AB, Year-end report 1 July 2024 – 30 June 2025

Summary of year-end report Fourth quarter (2025-04-01 – 2025-06-30) · Net sales amounted to SEK 0.0 million (0.0) · Operating profit amounted to SEK -1.6 million (-1.6) · Earnings per share* SEK -0.08 (-0.07) · European patent granted for GMP manufacture of Osteodex · The majority so far in the myeloma study (67%) have achieved stable disease. No significant side effects Full year (2024-07-01 – 2025-06-30) · Net sales amounted to SEK 0.0 million (0.0) · Operating profit amounted to SEK -5.3 million (-5.5) · Earnings per share* SEK -0.26 (-0.25) · Cash

DexTech Medical's Myeloma Study, Dose Group 2

The study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels of ODX are studied, 3mg/kg body weight, 6mg/kg, and 9mg/kg. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital Huddinge. Dr Dorota Knut is the principal investigator at the Department of Hematology at Uddevalla Hospital. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University Hospital Solna, NKS.  Adult

DexTech Medical's patent application regarding GMP manufacturing of OsteoDex is approved

OsteoDex is DexTech's lead candidate for the treatment of castration-resistant prostate cancer and has completed clinical phase 2. In October 2023, the Company filed a patent application with the EPO (European patent office, application No. 23203437.1). The application concerned GMP (Good Manufacturing Practice) manufacturing of OsteoDex. The application has now been approved, and a patent has been granted. The patent is of great importance for the continued clinical development of OsteoDex and future market exclusivity. The patent is valid until 2045 and is very positive for the Company's

DexTech Medical AB Interim report July 1, 2024 - March 31, 2025

Summary of the third quarter (2025-01-01 – 2025-03-31) · Net sales amounted to MSEK 0,0 (0,0) · Operating profit/loss amounted to MSEK -1,3 (-1,5) · Earnings per share* SEK -0.07 (-0.08) Summary of the nine-month period (2024-07-01 – 2025-03-31) · Net sales amounted to MSEK 0,0 (0,0) · Operating profit/loss amounted to MSEK -3,7 (-3,9) · Earnings per share* SEK -0.18 (-0.18) · Cash and cash equivalents at the end of the period amounted to MSEK 15,6 (19,0) * Before and after dilution. Earnings per share: Profit for the period divided by the average number of

DexTech Medical's myeloma study, strong follow-up results

The study is being conducted at Karolinska University Hospital Huddinge and Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels are being studied. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital Huddinge. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University Hospital Solna, NKS. Inclusion criteria include adult MM patients with relapsed treatment-resistant disease, who received 1–5 prior lines of therapy. The primary objective

DexTech Medical AB Half-year report July 1 - December 31, 2024

Summary of the second quarter (2024-10-01 – 2024-12-31) · Net sales amounted to MSEK 0,0 (0,0) · Operating profit/loss amounted to MSEK -1,1 (-1,4) · Earnings per share* SEK -0,05 (-0.06) * Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year. Summary of the first half-year (2024-07-01 – 2024-12-31) · Net sales amounted to MSEK 0,0 (0,0) · Operating profit/loss

DexTech Medical is funded through Q4, 2026

Regarding the ongoing Phase 1 study investigating the efficacy of OsteoDex in patients with progressive treatment-resistant multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond to existing treatment. The study is being conducted at Karolinska University Hospital Huddinge and Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels are being studied. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital Huddinge. Analysis of

DexTech Medical AB, Bulletin from the Annual General Meeting

Today, October 31, 2024, the Annual General Meeting of DexTech Medical AB was held. All resolutions were passed with the required majority. Resolution on adoption of the income statement and balance sheetThe AGM resolved to adopt the presented income statement and balance sheet. Resolution regarding appropriation of the company's result in accordance with the adopted balance sheetThe AGM resolved to allocate the company's result in accordance with the Board of Directors' proposal, and that no dividend be paid for the financial year 2023/2024. Resolution on discharge from

DexTech Medical AB, Interim report July 1- September 30, 2024

Summary of the first quarter (2024-07-01 – 2024-09-30) · Net sales amounted to MSEK 0,0 (0,0) · Operating profit/loss amounted to MSEK -1,3 (-1,1) · Earnings per share* SEK -0.06 (-0.05) · Cash and cash equivalents at the end of the period amounted to MSEK 17,9 (19,0) * Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year. Comments from the CEO  The latest results

DexTech Medical AB, Invitation to open Annual General Meeting and notice

On Thursday, October 31, 2024, DexTech Medical AB ("DexTech") will hold its Annual General Meeting. Subject to availability, non-shareholders are also welcome to participate without voting rights. At the meeting, the founders, CEO Anders R Holmberg and Medically Responsible Professor Sten Nilsson, among others, will present the company and the clinical situation regarding prostate cancer and multiple myeloma. There will be an opportunity to ask questions to DexTech's Board of Directors and management. Formal notice of the Annual General Meeting is available further down in this press

DexTech Medical AB: Annual Report 2023-07-01 - 2024-06-30

The Board of Directors and the CEO of Dextech Medical AB (DexTech), org.nr. 556664-6203, with its registered office in Stockholm, hereby submits the Annual Report for the financial year 2023-07-01 - 2024-06-30. For more information about DexTech, please contact: Gösta Lundgren - CFO DexTech Medical AB Phone: +46 (0) 707104788 E-mail: gosta.lundgren@dextechmedical.com  DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The lead candidate is OsteoDex for the treatment of

DexTech Medical AB, Year-end report July 1, 2023 - June 30, 2024

Summary of year-end report Fourth quarter (2024-04-01 – 2024-06-30) · Net sales amounted to SEK 0.0 million (0.0) · Operating profit amounted to SEK -1.6 million (-1.3) · Earnings per share* SEK -0.07 (-0.06) Full year (2023-07-01 – 2024-06-30) · Net sales amounted to SEK 0.0 million (0.0) · Operating profit amounted to SEK -5.5 million (-4.9) · Earnings per share* SEK -0.25 (-0.25) · Cash and cash equivalents at the end of the financial year amounted to SEK 19.0 (25.2) million * Before and after dilution. Earnings per share: Profit for the period divided

DexTech Medical AB announces continued positive results from myeloma study

The Phase 1 study examines the effect of OsteoDex on patients with progressive multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond to existing treatment. The first dose group (3mg/kg) is now ready, and the DMC (Data Monitoring Committee) has approved the start of dose group 2 (6mg/kg). DMC assesses all analysis results to decide on the next higher dose. No side effects related to OsteoDex have been noted. All patients show a decrease in skeletal biomarkers. Three out of four patients have stable disease after completion of treatment (stable = no

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe